Publications
Eidos Publications & Presentations
-
Patient and Family Experience of ATTR Amyloidosis: Results of Two Focus Groups
HFSA 2020 Annual Scientific Meeting; Rintell, David et al.; 2020 -
AG10 in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): Further analyses of 15-month follow-up of Phase 2 open label extension
International Symposium on Amyloidosis; Judge, Daniel P. et al.; 2020 -
ATTRibute-CM: A randomized, double-blind, placebo-controlled, multi-center, global Phase 3 study of AG10 in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
American Heart Association Scientific Sessions; Gillmore, Julian D. et al.; 2019 -
Differential Ex Vivo Stabilization Of Transthyretin By AG10 And TafamidisIn Samples From Patients With Moderately Or Severely Destabilizing Mutations
American Heart Association Scientific Sessions; Wong, Paul W. et al.; 2019 -
Differential Transthyretin Binding, Kinetic Stability and Additive Ex Vivo Stabilization by AG10 Compared to Tafamidis
American Heart Association Scientific Sessions; Ji, Alan X. et al.; 2019 -
Long-term safety and efficacy of AG10 in ATTR-CM: Phase 2 Open Label Extension
American Heart Association Scientific Sessions; Judge, Daniel P. et al.; 2019 -
First‐in‐Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers
Clinical Pharmacology in Drug Development; Fox, Jonathan C. et al.; 2019 -
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy
Journal of the American College of Cardiology; Judge, Daniel P. et al.; 2019
-
AG10, A Novel, Potent, and Selective Transthyretin Stabilizer, Is Well-Tolerated at Doses Resulting in Target Therapeutic Blood Levels, and Demonstrates Clinical Proof-of-Concept in Healthy Volunteers
Heart Failure Society of America Annual Meeting; Hellawell, Jennifer L. et al.; 2018 -
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis
Journal of Medicinal Chemistry; Miller, M. et al,; 2018 -
AG10 Potently and Selectively Stabilizes Transthyretin in vitro and Upon Oral Dosing in Dogs: Potential for Treating Transthyretin Amyloidosis
American Heart Association; Sinha, U. et al.; 2017 -
AG10 Stabilizes Pathogenic TTR Variants With High Potency - Potential for an Effective Treatment for ATTR Cardiomyopathy
American Heart Association; Graef, I.A. et al.; 2017 -
AG10, an orally available, novel transthyretin (TTR) stabilizer: integrated preclinical evaluation predicts a highly effective treatment for TTR amyloid cardiomyopathy
European Society of Cardiology; Alhamadsheh, M. et al.; 2017 -
AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
Proceedings of the National Academy of Sciences; Penchala, S.C. et al.; 2013 -
Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity.
Science Translational Medicine; Alhamadsheh M.M et al.; 2011